Chr. Hansen is followed by a number of financial analysts that regularly publish commentary, financial forecasts and recommendations on the stock.
Once a quarter, Chr. Hansen compiles a consensus which reflects the average of all available estimates on Chr. Hansen’s future financials. The consensus is collected – without any claim of being exhaustive – and published on the website prior to quarterly results publication.
The Q3 2018/19 consensus will be published here on July 1, 2019.
Consensus overview of Group estimates
|Q2 2018/19||FY 2018/19||FY 2019/20||FY 2020/21||FY 2021/22||FY 2022/23|
|Revenue in EUR m||288||1,195||1,304||1,424||1,556||1,699|
|Organic growth in %||10%||10%||9%||9%||9%||9%|
|EBIT margin b.s.i. in %||28.1%||29.9%||30.6%||31.1%||31.6%||32.0%|
|Free cash flow in EUR m||203||231||260||290||328|
Further details such as estimates for our business areas, highest and lowest estimates as well as the number of inputs can be found in the below Excel file.
Disclaimer: The consensus has been issued by Chr. Hansen for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding our revenues, earnings and business developments. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Chr. Hansen gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.